Author:
Liu Yingjie,Chu Zhenxing,Wang Hongyi,Huang XiaoJie,Chen YaoKai,Wang Hui,Zou Dehua,Jiang YongJun,Geng WenQing,Hu Qinghai,Zhou Baosen,Shang Hong
Abstract
Abstract
Introduction
Evidence on the willingness of men who have sex with men (MSM) with oral pre-exposure prophylaxis (PrEP) experience, especially those with suboptimal adherence, to take long-acting injectable PrEP (LAI-PrEP) is critical to guide future LAI-PrEP implementation.
Objective
The objective was to assess the willingness of MSM with oral PrEP experience to take LAI-PrEP.
Methods
MSM who participated in the China Real-world Study of Oral PrEP (CROPrEP) were enrolled in this study. Information on the willingness of MSM to take LAI-PrEP and potential correlates was collected using a structured online questionnaire. The main outcomes were the willingness of MSM to take LAI-PrEP and its association with HIV-related behaviours, sexually transmitted infections, and oral PrEP history. Logistic regression was used to identify correlates of the willingness of MSM to take LAI-PrEP.
Results
A total of 612 former CROPrEP participants (FCPs) were included in this study. There were 315 (51.5%) daily oral PrEP (D-PrEP) users and 297 (48.5%) event-driven oral PrEP (ED-PrEP) users at the last follow-up. Most FCPs (77.8%) were willing to take free LAI-PrEP. FCPs with no less than two sexual male partners (aOR = 1.54, [95% CI: 1.04, 2.29], P = 0.031), those with male partners with unknown HIV statuses (aOR = 2.04, [95% CI: 1.31, 3.18], P = 0.002), those with recreational drug use (aOR = 1.58, [95% CI: 1.05, 2.40], P = 0.030), and those with HSV-2 positivity (aOR = 2.15, [95% CI: 1.30, 3.57], P = 0.003) were more willing to take LAI-PrEP, while ED-PrEP users (aOR = 0.66, [95% CI: 0.45, 0.98], P = 0.037) and FCPs with suboptimal oral PrEP adherence (aOR = 0.58, [95% CI: 0.36, 0.94], P = 0.026) were less willing to take LAI-PrEP.
Conclusion
LAI-PrEP has good prospects for expanding PrEP coverage. However, FCPs with suboptimal oral PrEP adherence are less likely to take LAI-PrEP. Further intervention and implementation efforts are needed to improve the willingness of MSM to use LAI-PrEP, and sexual health should be considered during the discussion about PrEP initiation.
Funder
National Natural Science Foundation of China
Liaoning Revitalization Talents Program
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference43 articles.
1. WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva: World Health Organization; 2015 Sep. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK327115/].
2. UNAIDS, UNAIDS data 2021. Available from: [https://www.unaids.org/en/resources/documents/2021/2021_unaids_data].
3. Huang X, Hou J, Song A, Liu X, Yang X, Xu J, et al. Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: a systematic review and meta-analysis. Front Pharmacol. 2018;9:799.
4. Buchbinder SP, Liu AY. CROI 2018: Epidemic Trends and Advances in HIV Prevention. Top Antivir Med. 2018;26(1):1–16.
5. AIDS Vaccine Advocacy Coalition (AVAC). Global PrEP Use Landscape as of March 2022. Available from: [https://www.prepwatch.org/resource/global-prep-tracker/].